Clopixol-Acufas solution in oil 50mg/ml 1ml, 5pcs

Composition

1 ml:

– zuclopentixol acetate 50 mg

Auxiliary substances:

triglycerides.

Pharmacological action

Pharmaceutical group:

antipsychotic agent (neuroleptic).

Pharmaceutical action:

Antipsychotic agent (neuroleptic), a derivative of thioxanthene. Clopixol has a pronounced antipsychotic and specific inhibitory effect.

Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and subacute psychoses. Tolerance to the non-specific sedative effect of the drug occurs quickly.

Due to its specific inhibitory effect, the drug is especially indicated for agitation, anxiety, hostility or aggressiveness.

A single injection of Clopixol-akufaz provides a pronounced and rapid relief of psychotic symptoms. The duration of the antipsychotic effect of the drug after one injection is 2-3 days.

The non-specific sedative effect manifests itself in 2 hours, reaches a maximum in about 8 hours, then significantly decreases and is poorly manifested with repeated injections.

The therapeutic effect of Clopixol depot is significantly more prolonged than that of Clopixol. This allows us to confidently conduct continuous antipsychotic treatment with Clopixol depot, which is especially important for patients who do not perform medical appointments.

Clopixol depot prevents the development of frequent relapses associated with arbitrary interruption of oral medication by patients.

Indications

Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions and thinking disorders; states of agitation, increased anxiety, hostility, aggressiveness.

Use during pregnancy and lactation

Contraindicated. Nursing mothers should stop breastfeeding.

Contraindications

Chronic hepatitis; severe cardiovascular diseases.

Side effects

Extrapyramidal disorders, tardive dyskinesia, neuroleptic malignant syndrome, drowsiness, dizziness, dry mouth, accommodation disorders, urinary retention, constipation, tachycardia, orthostatic hypotension, changes in liver tests are possible.

Interaction

Increases the sedative effect of alcohol, barbiturates and other drugs that depress the central nervous system, reduces-levodopa and other adrenergic agents.

Weakens the hypotensive effect of guanethidine and its analogues.

Metoclopramide and piperazine increase the risk of extrapyramidal disorders.

How to take, course of use and dosage

Clopixol-akufaz is prescribed as a deep intramuscular injection into the upper outer quadrant of the gluteal region. Local portability is good. The dosage is selected individually depending on the patient’s condition.

The recommended volume of intramuscular injection is 1-3 ml (50-150 mg). If necessary, repeated injections are performed at intervals of 2-3 days. In some patients, an additional injection may be given 24-48 hours after the first injection.

When switching to treatment Oral Clopixol 2-3 days after the final injection Clopixol-akufaz (100 mg injections) the patient should be given an oral daily dose of 40 mg, if possible in several doses.

If necessary, the dose can be increased by 10-20 mg every 2-3 days to 75 mg/day or more.

Overdose

Symptoms:  drowsiness, hypo – or hyperthermia, hypotension, extrapyramidal symptoms, convulsions, shock, coma.

Treatment:  symptomatic and supportive treatment.

Measures should be taken to maintain the functioning of the respiratory and cardiovascular systems.

Do not use epinephrine (epinephrine), as this can lead to a subsequent decrease in blood pressure.

Seizures can be stopped with diazepam, and extrapyramidal symptoms with biperiden.

Special instructions

Neuroleptic malignant syndrome (NMS) is a rare but possible complication with a fatal outcome when using neuroleptics.

The main characteristics of NMS are hyperthermia, muscle rigidity and impaired consciousness in combination with dysfunction of the autonomic nervous system (labile blood pressure, tachycardia, increased sweating).

In addition to immediate discontinuation of antipsychotic medications, general supportive measures and symptomatic treatment are essential.

Form of production

Clopixol-akufaz solution for intravenous use (oil) of yellowish color, transparent, practically free of particles.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 30 °C

Shelf life

2 years

Active ingredient

Zuclopentixol

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection